Yatharth Hospit. Q1 FY27 Earnings Call — Analysis (NSE: YATHARTH)
Yatharth Hospital reports record Q1 FY27 revenue of ₹392.7 Cr (+51% YoY) and early EBITDA breakeven in acquired Faridabad hospital, signaling successful integration and operating momentum.
Result quality: watch — Margin pressure. Management sentiment: optimistic.
The take
Q1FY27 Revenue ₹392.7 Cr ( +51% YoY ) . New guidance — FY27 fy27 revenue growth rate surpass 37% . New story: Acquisition integration and rapid ramp-up .
Results
Consolidated revenue ₹392.7 Cr (+51% YoY, +15% QoQ); EBITDA ₹91.7 Cr (+39% YoY); PAT ₹45.4 Cr; EBITDA margin 23.3% (adjusted 28.1% excl. New Delhi & Faridabad Sec 20); ARPOB ₹34,758 (+7% YoY).
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue | ₹392.7 Cr | +51% | yoy · Q1FY27 |
| Revenue (QoQ) | ₹392.7 Cr | +15% | qoq · Q1FY27 |
| EBITDA | ₹91.7 Cr | +39% | yoy · Q1FY27 |
| PAT | ₹45.4 Cr | none · Q1FY27 | |
| EBITDA Margin | 23.3% | point_in_time · Q1FY27 · Q1FY27 | |
| Adjusted EBITDA Margin (excl New Delhi & Faridabad Sec 20) | 28.1% | point_in_time · Q1FY27 · Q1FY27 | |
| ARPOB | ₹34,758 | +7% | yoy · Q1FY27 |
| Occupancy | 68% | point_in_time · Q1FY27 · on census beds 1,820 | |
| Newer Hospitals Revenue Contribution | 27% | none · Q1FY27 · of group revenue |
Guidance
FY27 EBITDA margin expected at ~24%+; revenue growth to surpass last year’s 37% YoY; ARPOB growth 9-10% YoY; 5,000-bed target likely in ~2.5 years vs earlier 3 years; Model Town hospital breakeven by Q3-Q4 FY27; one new acquisition planned this fiscal.
What management committed to
- FY27 consolidated EBITDA margin will be upwards of 24%. — upwards of 24%, FY27
- FY27 revenue growth will surpass last year's 37% YoY growth. — surpass 37%, FY27
- FY27 ARPOB growth will be 9-10% YoY. — 9% to 10%, FY27
- 5,000 bed capacity target to be achieved in approximately 2.5 years, earlier than the previously stated 3 years. — 5,000 beds, approximately 2.5 years
- [Gurugram] 250-bed hospital will commence operations by Q1 of next fiscal (Q1FY28). — Q1FY28
- [New Delhi Model Town] hospital will achieve operational breakeven between Q3 and Q4 FY27. — FY27
- [Faridabad Sector 20] hospital EBITDA margin will reach 15-20% within 15-18 months after breakeven (i.e., breakeven achieved Q1FY27, so target by Q2FY28 to Q3FY28). — 15% to 20%, 15-18 months after breakeven
- At least one new hospital acquisition will be added in FY27. — at least one, FY27
- Brownfield expansions at [Greater Noida and Noida Extension] (450 beds) will start coming onstream in 15-18 months. — 450 beds, 15-18 months
- Group net debt will not exceed 2x trailing 12-month EBITDA. — 2x, going forward
Key themes
Acquisition ramp-up and margin recovery
How the narrative shifted
- Acquisition integration and rapid ramp-up: Management portrayed its acquisition playbook as proven, with Faridabad Sector 20 and Agra turning profitable faster than expected, reinforcing the ability to acquire, integrate, and turnaround assets.
- Payer mix improvement towards private pay: New hospitals deliberately kept government business below 10%, driving ARPOB towards ₹50,000; existing hospitals also reducing government volumes to improve realizations.
- Oncology as high-end specialty driver: Oncology already ~10% of group revenue from one LINAC; adding two more LINACs to deepen clinical capabilities and boost ARPOB.
- Margin recovery through operating leverage: Management emphasized that new hospitals will reduce EBITDA drag as they scale, but incremental margins from mature hospitals offset continued new hospital start-up costs.
- Regulatory uncertainty on room charge caps: Played down proposed panel recommendation as unlikely to materially impact, citing past government support and piecemeal implementation of similar interventions.
- International patient diversification: Early-stage initiative to open information centres and post marketing staff in CIS and Africa, aiming to improve payer mix and ARPOB over time.
Operational commentary
- Faridabad Sector 20 hospital turned EBITDA positive in just 9 months, beating the 12-14 month expectation, with monthly revenue run-rate of ₹12-13 Cr and ARPOB near ₹40,000 (target ₹45,000-50,000).
- New Delhi Model Town hospital reached ARPOB near ₹50,000 and monthly revenue run-rate of ₹8 Cr, on track for operational breakeven in 15-17 months from acquisition.
- Agra acquired hospital achieved 20%+ EBITDA margin in its first full quarter post-integration, with revenue run-rate of ₹9-10 Cr, demonstrating rapid turnaround capability.
- Gurugram greenfield 250-bed hospital construction on track to commence operations by Q1 FY28, targeting ARPOB of ₹50,000+.
- Brownfield expansion of ~450 beds at Greater Noida and Noida Extension to start coming online in 15-18 months, taking total announced capacity to 3,200+ beds.
- Oncology capability expanding: second LINAC to be added at Faridabad Sector 20, followed by New Delhi, leveraging existing oncology contribution of ~10% of group revenue from one LINAC.
- International patient outreach initiated: first Yatharth Information Center opened in Uzbekistan; senior marketing presence in Africa; five OPD centres planned across CIS and Africa.
- Maiden interim dividend (5% of face value) and first ESOP scheme (2026) approved, reflecting confidence in cash generation and talent retention.
- Payer mix at new hospitals remains above 90% cash and private insurance; group government mix steady at ~40% despite volume decline due to CGHS rate revision.
Analyst Q&A
Q. Full year FY27 revenue and EBITDA margin guidance
Management stated: “I think for the full year, FY27, we are on track for the guidance that we've already done... easily surpass that growth [37% YoY]... the company is on track close to upwards of 24% EBITDA margin for the full FY27 is concerned.”
Q. Impact of proposed panel recommendation to cap hospital room charges
Management called for more clarity and noted past instances where government supported private sector (CGHS rate revision), adding “It's just a proposal and think long way than even close to a certain part of it being implemented as of yet.” No impact quantified.
Q. Reason for low occupancy at Delhi Model Town and timeline for ramp-up
Explained that census beds increased from 100 to 150 this quarter, making occupancy appear lower; reiterated breakeven timeline of Q3-Q4 FY27 and confidence in ramp-up.
Q. Consolidated EBITDA margin returning to 28% and operating leverage quantification
Management clarified they are not targeting 28% consolidated margin soon due to continued new hospital additions; incremental EBITDA margin from mature occupancy ramp-up at Faridabad Sector 20 seen at 22-23%.
Research and educational content only. Not investment advice.